Health

Dr. Reddy's & Gilead partner for global HIV drug access

Article Image

Dr. Reddy’s Laboratories (NYSE:RDY) has signed a voluntary licensing agreement with Gilead Sciences Ireland UC, allowing it to manufacture and commercialize Lenacapavir in India and 120 other countries.

Lenacapavir, approved by the USFDA for treating multi-drug resistant HIV-1 in heavily treatment-experienced adults, is also under investigation for potential use in HIV prevention.

"Lenacapavir marks an important milestone for Dr. Reddy’s in patient access and affordability for pre and post-exposure treatment of HIV. The collaboration with Gilead will help us make this latest treatment option available to patients in 120 primarily low- and lower- middle income countries, including in India," said Deepak Sapra, CEO-API & Services, Dr. Reddy’s Laboratories.

The agreement aims to address high disease burdens in low- and middle-income countries.

Following the announcement, Dr. Reddy’s Laboratories share price held steady at $79.56.

Disclaimer
Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.
Publisher
Grafa